DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant’s election without traverse of the method of Claims 78 and 80-98 in the reply filed on 24 August 2026 is acknowledged.
Status of the Claims
Claims 78 and 80-98 are pending, presented for examination, and rejected as set forth in greater detail below.
Priority
The instant application is a National Stage entry of International application PCT/US2023/064139 filed 10 March 2023, which claims the benefit of Provisional U.S. applications 63/390,036 filed 18 July 2022, and 63/318,822 filed 11 March 2022.
Claim Interpretation
Applicants claims are directed to methods of treating eye disease by the administration to the eye of an insert comprising vorolanib which is configured to release a defined amount of vorolanib per day for at least 90 days, and which erodes by at least 10% within 95 days of insertion. Dependent claims 80-85 recite a variety of objectives the treatment step recited by Claim 78 is to achieve; applicants are reminded that a “whereby clause in a method claim is not given weight when it simply expresses the intended result of a process step positively recited.” Hoffer v. Microsoft Corp., 405 F.3d 1326, 1329, 74 USPQ2d 1481, 1483 (Fed. Cir. 2005) (quoting Minton v. Nat’l Ass’n of Securities Dealers, Inc., 336 F.3d 1373, 1381, 67 USPQ2d 1614, 1620 (Fed. Cir. 2003)). Claims 86 and 87 identify the patient population to be treated. Claims 88-92 describe structural elements the device containing the vorolanib is to possess. Claims 93-95 place limitation on the vorolanib to be included in the device. Claims 96 and 97 describe a manner of administration and physical dimensions the device is to possess. Claim 98 describes the device to be used in so-called “product-by-process” terminology. Applicants are reminded that “even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process.” In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985). As such, art describing a PVA/vorolanib matrix will be sufficient to address the limitations of these claims.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 78, 80-85, and 88-98 are rejected under 35 U.S.C. 103 as being unpatentable over Guo (U.S. PGPub. 2018/0353431), in view of Dan (Handong Dan, et al, CM082, A Novel VEGF Receptor Tyrosine Kinase Inhibitor, Can Inhibit Angiogenesis in vitro and in vivo, 136 Microvasc. Res. 104146 (19 February 2021).
Guo describes bioerodible drug delivery devices to be implanted in a patient at or near an area to be treated. (Abs.). Guo indicates that these devices are particularly useful in the treatment of eye diseases or disorders. [0004; 0006-07; 0033; 0053; 0056]. Age-related macular degeneration and ocular neovascularization are enumerated among the diseases treatable with these devices, which may deliver therapeutic agents for periods of three months or more. [0044-45]. Guo indicates that for ocular administration, particularly for delivery to the vitreous of the eye such as by intravitreal injection, the implants should be no longer than 7mm. [0049; 0056]. Guo describes using a needle having a gauge of 25 or larger to inject a cylindrical device into the desired location of the eye. [0033-34]. Guo indicates that an advantage of these devices is that they degrade in vivo over time into harmless byproducts, avoiding the need for removal of the device once administration of the pharmaceutically active agent is complete. [0017]. Devices where a drug-containing matrix of biodegradable polymer such as the PVA of the instant claims are contemplated, and specifically devices which contain between about 1-20% polymer by weight of the device, a range overlapping and therefore rendering obvious that of the instant claims. [0018-19]; See In re Peterson, 315 F.3d 1325, 1329 (Fed. Cir. 2003) (“A prima facie case of obviousness typically exists when the ranges of a claimed composition overlap the ranges disclosed in the prior art.”). Among the expansive classes of pharmaceutical agents which Guo contemplates including in these devices is the tyrosine kinase inhibitors. [0022-23]. Guo indicates that in addition to the drug core/matrix, these devices may be provided by an exterior polymeric coating of, among others, PVA. [0025]. Guo describes an exemplary embodiment where a tyrosine kinase inhibitor is combined with a 10% PVA solution to forma granulate which was then extruded into a tubular shape which was then dried and cured by being heat treated at 120°C for two hours, then cut into .35mm lengths. [0057-59]. Guo describes a number of variables known to control the rate and duration of drug release from the devices, including but not being limited to the length of the device, the type of polymer used, and whether the polymer is heat-treated to control or adjust the release rate of the pharmaceutically active agents contained therein. [0046]. Therefore, while not describing the erosion rate of Claim 1, the rate of release of claim 95, the teachings of Guo establish these are metrics which fall within the ability of skilled artisan to manipulate through the routine experimentation of a variety of known factors, and therefore prima facie obvious. See In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (indicating that where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.).
Guo therefore suggests the use of PVA/receptor tyrosine kinase inhibitor implants of 7mm in length injectable through a 25 gauge needle into the vitreous of the eye containing between 1-20% PVA, which is either uncoated or coated by an additional PVA layer, to treat AMD. Guo, however, does not specify that the drug to be used is vorolanib.
This is cured by the teachings of Dan, which indicates that CM082, synonymous with vorolanib, was at the time the instant application was filed known to be a VEGF receptor tyrosine kinase inhibitor taught to be useful in the treatment of neovascular eye diseases including age-related macular degeneration by the significant inhibition of choroidal neovascularization in vivo. (Pg. 1, 6). While not indicating any particular dosage of vorolanib, by describing the agent as effective in preventing the neovascularization characteristic of age-related macular degeneration, Dan establishes the amount of such a drug to be delivered is a result-effective variable suitable for optimization through little more than routine experimentation. See Aller, supra; see also Ariosa Diagnostics, Inc. v. Sequenom, Inc., 809 F.3d 1282, 1293 (Fed. Cir. 2015) (indicating that every ordinary artisan in medicine performs "merely routine optimization of drug dosage to maximize therapeutic effect.").
It would have been prima facie obvious to have utilized vorolanib (CM082) of the instant claims as the receptor tyrosine kinase inhibitor of Guo, and provided such a pharmaceutically active agent as a PVA/receptor tyrosine kinase inhibitor implants of 7mm in length injectable through a 25 gauge needle into the vitreous of the eye containing between 1-20% PVA, which is either uncoated or coated by an additional PVA layer, to be used in the treatment of AMD. This is because each of the elements of the present claims, absent the specification of vorolanib as the tyrosine kinase inhibitor, are described by Guo as desirable elements of an injectable ocular therapeutic device. It must be remembered that “[w]hen a patent simply arranges old elements with each performing the same function it had been known to perform and yields no more than one would expect from such an arrangement, the combination is obvious.” KSR v. Teleflex, 127 S.Ct. 1727, 1740 (2007) (quoting Sakraida v. A.G. Pro, 425 U.S. 273, 282 (1976)). “[W]hen the question is whether a patent claiming the combination of elements of prior art is obvious,” the relevant question is “whether the improvement is more than the predictable use of prior art elements according to their established functions.” (Id.). The selection of vorolanib as the tyrosine kinase inhibitor of Guo appears little more than the selection a known material for incorporation into a composition, based on its recognized suitability for its intended use. See Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 65 USPQ 297 (1945).
Claims 78 and 80-98 are rejected under 35 U.S.C. 103 as being unpatentable over Guo and Dan as applied to claims 78, 80-85, and 88-98 above, and further in view of Sherman (U.S. PGPub. 2017/0291935).
Guo and Dan, discussed in greater detail above, suggest treating AMD by the injection of a PVA/vorolanib implant of 7mm in length injectable through a 25 gauge needle into the vitreous of the eye containing between 1-20% PVA, which is either uncoated or coated by an additional PVA layer.
Neither Guo nor Dan, however, describe the subject to be treated as falling within any of the categories recited by Claims 86 or 87.
This is cured by the teachings of Sherman. Sherman establishes that ischemia and microvascular pathology are associated with ocular disorders including age-related macular degeneration, and reinforces the teachings of Guo and Dan concerning the use of antiangiogenic VEGF inhibitors in the treatment of AMD. [0005-06]. Sherman indicates that the treatment of AMD with these therapeutics can serve to treat subjects having category 1, 2, 3, or 4 AMD. [0011].
It would have been prima facie obvious to have used the vorolanib implants suggested by the teachings of Guo and Dan to treat patients having any combination of eyes with any of categories 1-4 AMD. This is because Sherman establishes that antiangiogenic VEGF inhibitors may be used to treat any of categories 1-4 AMD, making the use of the devices of Guo and Dan the selection of a known material for use in a method where the properties of the material are desirable, based on its recognized suitability for its intended use. See Sinclair, supra.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 78 and 80-98 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-14 of U.S. Patent No. 12,551,368 in view of Dan, discussed in greater detail above. The ‘368 patent claims are directed to the implants described in the method claims of the instant application, differing only in the fact that the ‘368 claims fail to describe the use of these implants in the treatment of ocular disease such as AMD. Because Dan establishes that Vorolanib is a VEGF Receptor Tyrosine Kinase inhibitor effective in the treatment of choroidal neovascularization and suggests its use in the treatment of ocular disease such as AMD, it would have been prima facie obvious for a skilled artisan to use the implants of the ‘368 patent to treat AMD.
Claims 78 and 80-98 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 53-55, 57, and 60-73 of copending Application No. 18/843,596 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the ‘596 application is more broadly directed to the treatment of “posterior ocular diseases” by the injection of the presently claimed vorolanib devices, among which the presently claimed AMD is counted a member. The subject matter of the instant claims and that of the ‘596 application therefore overlaps, rendering the subject matter encompassed by the present claims prima facie obvious of that of the ‘596 claims.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claims 78 and 80-98 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 161-186 of copending Application No. 18/843,571 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the ‘571 application is more broadly directed to the treatment of “posterior ocular diseases” by the injection of the presently claimed vorolanib devices, among which the presently claimed AMD is counted a member. The subject matter of the instant claims and that of the ‘571 application therefore overlaps, rendering the subject matter encompassed by the present claims prima facie obvious of that of the ‘571 claims.
Claims 78 and 80-98 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 110-128 of copending Application No. 19/458,141 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the ‘141 application is more broadly directed to the treatment of “posterior ocular diseases” by the injection of the presently claimed vorolanib devices, among which the presently claimed AMD is counted a member. The subject matter of the instant claims and that of the ‘141 application therefore overlaps, rendering the subject matter encompassed by the present claims prima facie obvious of that of the ‘141 claims.
Conclusion
No Claims are allowable.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEAN M BASQUILL whose telephone number is (571)270-5862. The examiner can normally be reached Monday through Thursday, 5:30 AM to 4 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached at (571) 272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SEAN M BASQUILL/Primary Examiner, Art Unit 1614